Nonsmall-cell lung cancer (NSCLC), which is usually in advanced stage when diagnosed, accounts for >70% of lung cancer.1 As we know, angiogenesis is a key process for cell growth, especially for the tumor growth.2 And the vascular epidermal growth factor (VEGF) can activate the downstream pathway to stimulate the proliferation of vessel endothelium via binding vascular epidermal growth factor receptor (VEGFR), thus leading to the growth of tumor. The gene discussed is KDR; the disease is lung cancer.